Table 3.

Adverse events in Patients with T2DM.

	LY3298176 0.5 mg N = 9	LY3298176 5 mg N = 9	LY3298176 5/5/10/10 mg N = 12	LY3298176 5/5/10/15 mg N = 12	Placebo N = 11	All N = 53
Any TEAE	5 (55.6)	7 (77.8)	10 (83.3)	11 (91.7)	3 (27.3)	36 (67.9)
Mild, events	15	17	54	87	6	179
Moderate, events	0	0	1	9	0	10
Severe, events	0	0	0	0	0	0
Serious adverse events	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Study discontinuation due to adverse events	0 (0.0)	3 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Any TEAEs in order of frequency
Vomiting	1 (11.1)	0 (0.0)	1 (8.3)	9 (75.0)	0 (0.0)	11 (20.8)
Decreased appetite	2 (22.2)	6 (66.7)	5 (41.7)	11 (91.7)	1 (9.1)	25 (47.2)
Diarrhoea	1 (11.1)	1 (11.1)	3 (25.0)	5 (41.7)	1 (9.1)	11 (20.8)
Abdominal distension	0 (0.0)	1 (11.1)	2 (16.7)	7 (58.3)	0 (0.0)	10 (18.9)
Nausea	1 (11.1)	1 (11.1)	1 (8.3)	6 (50.0)	0 (0.0)	9 (17.0)
Gastrooesophageal reflux disease	0 (0.0)	1 (11.1)	1 (8.3)	5 (41.7)	0 (0.0)	7 (13.2)
Eructation	0 (0.0)	0 (0.0)	1 (8.3)	4 (33.3)	0 (0.0)	5 (9.4)
Weight decrease	0 (0.0)	0 (0.0)	2 (16.7)	2 (16.7)	0 (0.0)	4 (7.5)
Dyspepsia	0 (0.0)	0 (0.0)	3 (25.0)	0 (0.0)	0 (0.0)	3 (5.7)
Headache	1 (11.1)	0 (0.0)	0 (0.0)	2 (16.7)	0 (0.0)	3 (5.7)
Abdominal pain	0 (0.0)	0 (0.0)	0 (0.0)	2 (16.7)	0 (0.0)	2 (3.8)
Dermatitis allergic	0 (0.0)	0 (0.0)	0 (0.0)	2 (16.7)	0 (0.0)	2 (3.8)
Hepatic enzyme increased	0 (0.0)	0 (0.0)	1 (8.3)	1 (8.3)	0 (0.0)	2 (3.8)
Pancreatic enzyme increased	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	1 (9.1)	2 (3.8)
Other adverse events
Total hypoglycaemia (≤70 mg/dL)	0 (0.0)	0 (0.0)	2 (16.7)	1 (8.3)	1 (9.1)	4 (7.5)
Severe hypoglycaemia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Acute pancreatitis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Injection site reaction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Data presented as n (%), unless otherwise noted. TEAE = treatment-emergent adverse event.